Explore 3 Stock Ideas & Industry Insights Download Free Report

Larimar Therapeutics Inc

Company price
3.015 USD 0.01 ( 0.50%)
Last update at 2026-11-17T20:51:00Z
VOLUME
1155962
Market Cap
406.18M

Momentum Score

…

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.90
Low
3.13
High
52 Week Price Range
2.71
Low
6.42
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Larimar Therapeutics Inc is a NASDAQ-listed biopharmaceutical company that, according to public disclosures, develops novel therapeutic programs. Long-term growth drivers may include progress in its clinical pipeline, licensing or partnership deals, and successful commercialization, which could support upside tied to program milestones.
Material investment risks include clinical trial setbacks, regulatory delays, high cash burn with likely financing needs, limited operating history and intense competition in specialty therapeutics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.05
ROE
-139.63%
Net Debt
-81.34M
ROCE
-204.42%
Diluted EPS TTM
-2.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -165.67M -80.60M -36.95M -35.35M -50.64M
Net income -165.67M -80.60M -36.95M -34.18M -50.31M
Selling general administrative 18.27M 17.61M 14.09M 12.28M 12.07M
Selling and marketing expenses - - 14.07M - -
Gross profit -0.35M -0.32M -0.31M - -
Reconciled depreciation 0.35M 0.32M 0.31M 0.32M 0.33M
Ebit -165.67M -80.60M -36.95M -36.84M -50.79M
Ebitda -165.32M -80.29M -36.64M -36.53M -50.47M
Depreciation and amortization 0.35M 0.32M 0.31M 0.32M 0.33M
Non operating income net other - - - 1.17M -
Operating income -172.50M -90.89M -41.76M -36.53M -50.47M
Other operating expenses 172.50M 90.89M 41.76M 36.53M 50.47M
Interest expense - - - -0.32M 0.33M
Income tax expense - - - -1.17M -0.33M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 172.50M 90.89M 41.76M 36.53M 50.47M
Cost of revenue 0.35M 0.32M 0.31M - -
Total other income expense net 6.82M 10.29M 4.81M 1.17M -0.17M
Net income from continuing ops -165.67M -80.60M -36.95M -35.35M -50.64M
Net income applicable to common shares - - - -35.35M -50.64M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 145.84M 200.22M 95.94M 126.41M 78.67M
Other current assets 4.42M 10.80M 3.38M 2.31M 2.11M
Total liab 67.76M 28.41M 14.21M 15.50M 14.25M
Total stockholder equity 78.08M 171.81M 81.72M 110.90M 64.41M
Other current liab 58.47M 20.87M 7.39M 8.41M 6.59M
Common stock 0.08M 0.06M 0.04M 0.04M 0.02M
Capital stock 0.08M 0.06M 0.04M 0.04M 0.02M
Retained earnings -434.83M -269.16M -188.55M -151.60M -116.25M
Other assets - - - 1.98M 2.01M
Cash 85.41M 33.22M 26.75M 26.82M 70.10M
Total current liabilities 64.80M 24.36M 9.51M 10.71M 8.85M
Net debt -81.34M -28.10M -21.20M -21.42M -64.09M
Short term debt 1.10M 1.06M 0.84M 0.61M 0.59M
Short long term debt total 4.07M 5.12M 5.55M 5.41M 6.00M
Other stockholder equity 512.78M 440.76M 270.15M 262.50M 180.65M
Property plant equipment - - - 0.83M 4.46M
Total current assets 142.02M 195.30M 90.17M 120.74M 72.20M
Net tangible assets - - - 110.90M 64.41M
Short term investments 51.44M 150.24M 60.04M 91.60M 0.00M
Net receivables 0.75M 1.05M - - 0.21M
Inventory - - - - -0.21M
Accounts payable 5.22M 2.42M 1.28M 1.69M 1.66M
Accumulated other comprehensive income 0.05M 0.15M 0.08M -0.03M -
Common stock total equity - - - 0.04M -
Retained earnings total equity - - - -151.60M -
Non currrent assets other 1.13M 1.20M 0.66M 1.98M 2.01M
Non current assets total 3.82M 4.92M 5.76M 5.67M 6.46M
Capital lease obligations 4.07M 5.12M 5.55M 5.41M 6.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 100.40M -85.39M 33.35M -90.86M 24.50M
Change to liabilities - - - 1.84M -0.97M
Total cashflows from investing activities 100.31M -85.39M 33.35M -90.96M 24.17M
Total cash from financing activities 65.09M 161.88M 0.03M 75.26M 19.89M
Change to operating activities - - - 1.64M 3.72M
Net income -165.67M -80.60M -36.95M -35.35M -50.64M
Change in cash 52.19M 5.74M -0.08M -43.27M 1.95M
Begin period cash flow 33.82M 28.09M 26.82M 71.44M 69.49M
End period cash flow 86.02M 33.82M 26.75M 28.16M 71.44M
Total cash from operating activities -113.20M -70.76M -33.46M -27.57M -42.10M
Issuance of capital stock 65.09M 161.81M 0.00M 75.26M 19.89M
Depreciation 0.35M 0.32M 0.31M 0.32M 0.33M
Other cashflows from investing activities - - 0.03M - -
Sale purchase of stock - - - 75.26M -
Other cashflows from financing activities 65.09M 0.08M 0.03M -90.96M 24.17M
Change to netincome - - - 6.62M 5.46M
Capital expenditures 0.09M 0.52M 0.16M 0.10M 0.33M
Cash flows other operating - - - -0.22M -
Cash and cash equivalents changes - - - -43.27M -
Change in working capital 47.10M 6.17M -2.51M 1.67M 2.75M
Stock based compensation 7.00M 8.80M 7.62M 6.62M 5.47M
Other non cash items -1.98M -5.45M -1.93M -0.82M -0.01M
Free cash flow -113.29M -71.28M -33.62M -27.67M -42.44M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
LRMR
Larimar Therapeutics Inc
0.01
0.50%
3.02 - - - 3.08 -4.13
NVO
Novo Nordisk A/S
-0.99
2.39%
40.60 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-3.90
0.73%
533.89 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
5.36
0.56%
957.76 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Larimar Therapeutics Inc

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004

844 511 9056

71

Name Title Year Born
Dr. Carole S. Ben-Maimon M.D. CEO, Pres & Director 1959
Mr. Michael Celano CPA Sec. & CFO 1959
Mr. John Berman VP of Fin. & Operations NA
Ms. Jennifer Spokes Johansson VP of Regulatory Affairs & Counsel NA
Dr. Nancy M. Ruiz Chief Medical Officer NA
Mr. Francis Michael Conway VP & Controller NA
Dr. Carole S. Ben-Maimon M.D. CEO, President & Director 1959
Mr. Michael Celano CPA Secretary & CFO 1959
Mr. John Berman Vice President of Finance & Administration NA
Ms. Jennifer Spokes Johansson Vice President of Legal & Compliance NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…